Antipsychotics

6 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs
0 on aging of 5 trials, 3 with no results posted

Human trial1
Humans3

Associations

Metabolic disorders

upin humans1

1 study

Antipsychotics raise the risk of metabolic disorders in humans.
“Pharmacotherapy used in psychiatry, particularly some antipsychotics (APs), may increase the risk of developing metabolic disorders.”
Review
Reducing the risk of obesity, diabetes, and metabolic disorders in patients treated with antipsychotics - recommendations of the Polish Psychiatric Association Part II: diagnostics and pharmacological treatment
Psychiatria polska30 Aug 2026

Trials

0 on aging of 5

In trials

Schizophrenia
Phase 4Terminated4 trials
Mental disorders
Phase 4Terminated1 trial
Psychotic disorders
Phase 4Status unknown1 trial

Stopped

NCT01592201TerminatedSchizophrenia
This study was early terminated due to insufficient enrollment required for hypothesis testing.
NCT02435095TerminatedSchizophrenia
slow patient recruitment, low patient-commpliance, high dropout rates,